New multi-million kronor agreement for Sprint Bioscience
Sprint Bioscience and LG Chem have signed a cooperation and licensing agreement for research, development and commercialization of drug candidates. “We’re delighted about the agreement with LG Chem, an ideal partner to further develop this programme,” says Dr Anders Åberg, Sprint Bioscience CEO.
– We are very pleased to have signed the agreement with LG Chem, a perfect partner to further develop this program. The agreement also confirms the quality of our drug research programs and the global scope of our network in the pharmaceutical industry, “says Dr. Anders Åberg, CEO of Sprint Bioscience.
The agreement applies to Sprint Bioscience’s early development program for NASH and metabolic diseases and gives the company approximately USD 2.5 million for the first 12 months. Sprint Bioscience is entitled to approximately $ 230 million in potential preclinical, clinical and net sales-based interim payments. In addition, Sprint Bioscience is entitled to receive royalties on worldwide net sales of any resulting products from the collaboration.
– We enter into this collaboration with Sprint Bioscience to expand our portfolio in NASH and other metabolic diseases, says dr. Jeewoong Son, CEO of LG Chem Life Sciences Company.
NASH (Non-Alcoholic Steatohepatitis) is a serious liver disease where there is currently no treatment. Sprint Bioscience is working on a new mechanism of action and a new target protein involved in fat storage in the liver and other tissues, inflammatory response and fibrosis in NASH. Something that provides the opportunity to develop treatments that can slow the development of both early and late stages of NAFLD (Non-Alcoholic Fatty Liver Disease) / NASH.